RT Journal Article
T1 Effectiveness of long-acting paliperidone palmitate in borderline personality disorder
A1 Palomares Mora, Nerea
A1 Montes Montero, Ana
A1 Díaz Marsa, Marina Francisca
A1 Carrasco Perera, José Luis
AB The aim of the present study is to test the efficacy of palmitate paliperidone long-acting injection for patients with borderline personality disorder (BPD). A total of 16 patients with BPD were treated with intramuscular paliperidone palmitate (IMPP) over 12 weeks. Effectiveness measures included the CGI-BPD, HARS, MADRS, BIS-11, and STAXI-2. Functional improvement was assessed using the Global Assessment of Functioning scale. A list of adverse events was provided to clinicians and patients. Treatment with IMPP was associated with a significant average reduction of 1.6 (95% confidence interval: 1192-2008; P>0.01) in CGI-BPD scores and an average increase of psychosocial functioning as scored by the Global Assessment of Functioning scale of 13.3 (95% confidence interval: 8.35-18.31; P>0.01) was obtained. The treatment decreased impulsive-disruptive behaviors and improved general functioning. An acceptable tolerance was observed. The average weight gain was clinically irrelevant despite being statistically significant. No other relevant adverse side effects were reported, with the exception of galactorrhea, which required suspension of treatment in three patients. IMPP seems to be a well-tolerated alternative to other second-generation antipsychotics in the treatment of BPD. More controlled studies replicating these results should be proposed in the future.
PB LIppincot williams and Wlikins
SN 0268-1315
YR 2015
FD 2015
LK https://hdl.handle.net/20.500.14352/131254
UL https://hdl.handle.net/20.500.14352/131254
LA eng
NO Palomares, Nereaa; Montes, Anaa; Díaz-Marsá, Marinab,c; Carrasco, José L.b,c. Effectiveness of long-acting paliperidone palmitate in borderline personality disorder. International Clinical Psychopharmacology 30(6):p 338-341, November 2015. | DOI: 10.1097/YIC.0000000000000095
DS Docta Complutense
RD 18 mar 2026